House lawmakers unveil bipartisan bill to cap insulin costs at $35 per month

A bipartisan group of House lawmakers introduced legislation Thursday to limit monthly out-of-pocket insulin costs to $35 for privately insured patients. The bill also would ban deductibles on certain insulin products and create a hotline for uninsured access. Two Republicans in competitive districts co-sponsored the measure, which mirrors a Senate bill that advanced earlier this summer.

EXPANDED:

The legislation mirrors a Senate companion that cleared the Health Committee this summer with 28 co-sponsors divided evenly between parties. The House version also prohibits deductibles on select insulin products, accelerates review of biosimilar alternatives, and establishes a hotline connecting uninsured patients with insulin resources.

The measure follows the 2022 Inflation Reduction Act, which capped Medicare beneficiaries' insulin costs at $35 monthly without Republican support. Roughly 40 million Americans live with diabetes. With the House in session just one more week before midterms, supporters see the lame-duck period and year-end spending negotiations as the most realistic path forward